Mainstream

Lineage Cell Therapeutics outlines manufacturing milestone and anticipates OpRegen 36-month data update while advancing OPC1 clinical plans

Lineage Cell Therapeutics outlines manufacturing milestone and anticipates OpRegen 36-month data update while advancing OPC1 clinical plans

Post ContentlctxRead More

You might also be interested in reading SpaceX looks to raise new funds at a $400B valuation level.

May 13, 2025
In Mainstream